DISEASE CHARACTERISTICS:

• Histologically proven malignant solid tumor not amenable to curative surgical therapy or radiation therapy
• No squamous cell histology
• No histology in close proximity to a major blood vessel
• No history of or known brain metastases, spinal cord compression, or carcinomatous meningitis
• No new evidence of brain or leptomeningeal disease on screening CT scan or MRI

PATIENT CHARACTERISTICS:

• ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100%
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• Creatinine ≤ 1.5 times ULN
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥100,000/mm³
• Hemoglobin ≥ 10.0 g/dL
• Calcium ≤ 12.0 mg/dL

• Urine protein:creatinine ratio ≤ 0.5 by urinalysis

  • Patients with urine protein:creatinine ratio > 0.5 must have proteinuria < 1,000 mg by 24-hour urine collection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy

• None of the following within the past 12 months:

  • Myocardial infarction
  • Severe/unstable angina
  • Severe peripheral vascular disease (claudication) or procedure on peripheral vasculature
  • Coronary/peripheral artery bypass graft
  • New York Heart Association (NYHA) grade III-IV congestive heart failure
  • Cerebrovascular accident or transient ischemic attack
  • Clinically significant bleeding
  • Deep venous thrombosis
  • Pulmonary embolism
• No ongoing cardiac dysrhythmias of NCI CTCAE ≥ grade 2, atrial fibrillation of any grade, or prolongation of the QTc interval to > 450 msec (males) or > 470 msec (females)
• No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
• No condition classified as NYHA grade III or IV

• No hypertension that cannot be controlled by medications

  • Blood pressure < 140/90 mm Hg
• No evidence of bleeding diathesis or coagulopathy
• No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
• No significant traumatic injury within the past 28 days
• No serious, non-healing wound, ulcer, or bone fracture
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
• No known HIV or AIDS-related illness
• No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation

PRIOR CONCURRENT THERAPY:

• Recovered from prior radiation therapy, surgery, or other prior therapy

• No prior bevacizumab or sunitinib malate (SU11248)

  • Other antiangiogenic therapies allowed
• No prior tyrosine kinase inhibitor of the VEGF receptor or bevacizumab for patients with metastatic renal cell carcinoma
• No major surgical procedures or open biopsy within the past 28 days
• No core biopsy within the past 7 days
• No radiation therapy or systemic therapy within the past 4 weeks

• No concurrent full-dose anticoagulants (e.g., warfarin)

  • Concurrent low-dose anticoagulation (e.g., prophylactic port patency) allowed
• No concurrent treatment on another clinical trial
• No other concurrent investigational drugs
• No concurrent major surgery
• No other concurrent anticancer agents or therapies, including chemotherapy, biological response modifiers, hormonal therapy, surgery, palliative radiation therapy, or immunotherapy